Research programme: prostaglandin EP4 receptor antagonists - RaQualia Pharma

Drug Profile

Research programme: prostaglandin EP4 receptor antagonists - RaQualia Pharma

Alternative Names: RQ-00000008

Latest Information Update: 31 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute pain; Autoimmune disorders; Cancer; Hypersensitivity; Inflammation; Inflammatory pain

Most Recent Events

  • 29 Oct 2014 Preclinical develolpment is ongoing in Japan
  • 09 Apr 2009 The programme is available for partnership and or/collaboration (
  • 08 Apr 2009 Preclinical trials in Inflammatory pain in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top